CNBC's Angelica Peebles reports from the American Society of Clinical Oncology, or ASCO, about an experimental pill that promises new hope for pancreatic cancer patients.
The drug is called daraxonrasib, and it blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases — a target that had eluded treatment for decades.
|
CNBC’s David Faber sat down with OpenAI ...
The 'Fast Money' traders react to Alphab...
Much has been made of the fact that ther...
“Don’t overlook emerging markets”: Tim U...
Are we in an ETF bust or boom? Innovator...
CNBC's Angelica Peebles reports from the...
Nvidia's Jensen Huang calls concerns of ...
----------------------------------------...
Nvidia is entering the PC market with a ...
Anthropic has confidentially submitted d...
Here are today’s top headlines: • NVIDIA...
The Vergecast is officially a daily show...
